GlassScriptPhysician profile
Nadeem N Vaidya
NPI 1578616520
$18,019.89
in general payments reported to CMS, 2019-2025
22 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,086 · 2020: $3,864 · 2021: $3,739 · 2022: $1,036 · 2023: $239 · 2024: $687 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $7,539.96 | 2019-2023 | Iluvien |
| Allergan, INC. | $4,416.33 | 2019-2022 | |
| Optos, INC. | $3,017.20 | 2019-2020 | |
| Genentech USA, INC. | $517.10 | 2021-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $439.98 | 2020-2024 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $391.57 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $281.60 | 2019-2022 | |
| Astellas Pharma US INC | $265.74 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $212.80 | 2019-2022 | |
| Dutch Ophthalmic, USA | $195.64 | 2019-2023 | Eva, Combined Machine, Tissueblue |
| Bausch & Lomb Americas INC. | $151.59 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $138.20 | 2022-2025 | Eylea Hd, Eylea |
| Genentech, INC. | $102.49 | 2024 | Vabysmo, Susvimo |
| Ani Pharmaceuticals, INC. | $80.36 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $76.71 | 2022-2025 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $38.54 | 2023 | Iheezo |
| Amgen INC. | $35.10 | 2024 | Tepezza |
| Boston Scientific Corporation | $33.08 | 2021 | |
| Vyera Pharmaceuticals, LLC | $20.54 | 2022 | |
| Horizon Therapeutics Plc | $13.58 | 2022 | |
| Abbvie INC. | $12.98 | 2023 | Ozurdex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.